Women who undergo hormone therapy for menopausal symptoms such as hot flashes may be able to increase bone mass and improve bone structure, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Georgios Papadakis, MD, of the Lausanne University Hospital in Lausanne, Switzerland point out that menopausal...
Doses can be tailored to compensate for individual risk factors, protect bone health Individualized supplement doses help protect pregnant women from vitamin D deficiency, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. The research found vitamin D supplements are less effective at raising vitamin D levels in pregnant...
Researchers call for further study to reduce risk of depression, side effects Men can take birth control shots to prevent pregnancy in their female partners, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Researchers are still working to perfect the combination of hormonal contraceptives to reduce the risk...
Exposure to the chemicals – even at very low doses — used in hydraulic fracturing, or fracking, may impair fertility, according to a study recently published in Endocrinology. The researchers, led by Susan C. Nagel, PhD, of the University of Missouri in Columbia, followed up on their previous work, in which they showed that 23...
The Endocrine Society on Thursday will host a Twitter chat focused on polycystic ovary syndrome (PCOS) to coincide with women’s health month, moderated by Society member Genevieve S. Neal-Perry, MD, PhD, who directs the University of Washington Medicine’s Reproductive Endocrinology and Infertility Center. Nearly 10 percent of women have PCOS, and it is one of the...
Birth Right: A Look at the First Uterus Transplant in the U.S.
Members in the News: Teresa Woodruff Participates in Reddit AMA
The initiation of a Phase 2b clinical trial evaluating the efficacy of novel oral drug candidate MLE4901, a first-in-class, non-hormonal therapy for the treatment of polycystic ovary syndrome (PCOS) was announced by Millendo Therapeutics, Inc. on August 17. There are currently no approved therapies for PCOS, which is the most common endocrine disease in women....